<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03815305</url>
  </required_header>
  <id_info>
    <org_study_id>441/UN2.F1/ETIK/2018/</org_study_id>
    <nct_id>NCT03815305</nct_id>
  </id_info>
  <brief_title>Effect of Centella Asiatica on Xerotic Skin in Diabetes Mellitus Type 2</brief_title>
  <official_title>Effect of Centella Asiatica on Xerotic Skin in Diabetes Mellitus Type 2: a Study on N(6)-Carboxymethyl-lysine, Interleukin 1-α, Dan Superoxide Dismutase in Stratum Corneum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the effect of Centella asiatica on hydration&#xD;
      status of lower leg skin of DM type 2 patients by measuring SRRC and Skin Capacitance in&#xD;
      correlation with AGEs CML, inflammation marker IL-1α, and oxidative stress SOD in stratum&#xD;
      corneum.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This ia a double blind randomized clinical trial on patients diagnosed with DM type 2 with&#xD;
      dry skin to assess the effect of Centella asiatica (CA) on dry skin in corellation with AGEs&#xD;
      CML, inflammation marker IL-1α, and oxidative stress SOD in stratum corneum after four weeks&#xD;
      of treatment. Subjects are divided into three groups of treatment. The first group treated&#xD;
      with oral CA and topical CA, second group treated with oral placebo and topical CA, and the&#xD;
      last group treated with oral and topical placebo. The total subjects in each treatment groups&#xD;
      are 53 subjects. The recruited subjects will be randomized to receive three different&#xD;
      treatments, consist of 1. First group (A) will receive combination of oral CA at 2x1100 mg&#xD;
      dose and 1% topical CA ointment. 2. Second group (B) will receive oral placebo and topical CA&#xD;
      1% ointment 3. Third group (C) will receive oral placebo and petroleum jelly as topical&#xD;
      placebo The recruited subjects will still receive the prescribed treatment for DM type 2. The&#xD;
      treatment for dry skin will be administered for 28 days. Randomization done by our supervisor&#xD;
      using computer program (RandlistR) by assigning code number for each subjects. The procedures&#xD;
      of treatment administration are explained below: 1. Every subject will receive 56 capsules&#xD;
      and 10 gram of ointment to be used in 2 weeks period. Subjects will also receive explanation&#xD;
      on how to take the drugs 2. Oral drug are taken 2 capsules (@ 550 mg) b.i.d over 12 hours. 3.&#xD;
      The ointment is applied two times a day 15 minutes after bath time. 4. The application have&#xD;
      to be distributed evenly on a specific 7 x 20 cms area on lower leg. All patients will be&#xD;
      given plastic cover to determine the area. 5. The estimation of ointment applied on every leg&#xD;
      is as much as ½ FTU or about 0,25 gram. 6. After 2 week period ended, subject will be given&#xD;
      the same treatment at follow-up visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">July 30, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Actual">January 12, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Skin Capacitance</measure>
    <time_frame>1 month (evaluated every 2 weeks)</time_frame>
    <description>SCap measured in (AU)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in SOD</measure>
    <time_frame>1 month (evaluated every 2 weeks)</time_frame>
    <description>Superoxide Dismutase (compared to total protein)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-1α</measure>
    <time_frame>1 month (evaluated every 2 weeks)</time_frame>
    <description>Interleukin-1α (compared to total protein)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in AGEs CML</measure>
    <time_frame>1 month (evaluated every 2 week)</time_frame>
    <description>Advanced Glycation End Product, N-(Carboxymethyl)lysine (compared to total protein)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in SRRC</measure>
    <time_frame>1 month (evaluated every 2 week)</time_frame>
    <description>Specified symptom sum score. Measuring dry skin using four variables (scale, roughness, redness, and cracking) in score ranged from 1 to 4 for each variable. The highest the value marks the driest skin</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Xerosis Cutis</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Topical CA and Placebo Oral Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient given 10gr 1% CA ointment and 56 pcs of placebo drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Petroleum Jelly and placebo oral drug</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient given 10gr petroleum jelly 100% topical ointment and 56 pcs of placebo drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Centella asiatica extract and Topical CA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient given 10gr 1% CA ointment and 56 pcs of drug containing CA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Centella Asiatica Extract</intervention_name>
    <description>centlla asiatica oral drug at 1100 mg dose</description>
    <arm_group_label>Centella asiatica extract and Topical CA</arm_group_label>
    <other_name>Oral CA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical CA</intervention_name>
    <description>1% centella asiatica ointment</description>
    <arm_group_label>Topical CA and Placebo Oral Drug</arm_group_label>
    <other_name>Centella asiatica ointment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Petroleum jelly</intervention_name>
    <description>vaseline album</description>
    <arm_group_label>Petroleum Jelly and placebo oral drug</arm_group_label>
    <other_name>Topical Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with Diabetes Mellitus Type 2&#xD;
&#xD;
          -  &lt;60 years old by the end of the study&#xD;
&#xD;
          -  suffered from dry skin on lower leg skin area, (minimum score= 3, measured using SRRC)&#xD;
&#xD;
          -  agree to not use any skin care product orally or topically on lower leg skin and any&#xD;
             other drugs (unless its part of diabetes mellitus management)&#xD;
&#xD;
          -  normal ankle brachial index value ranged from 0.91-1.3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  the presence of diabetic ulcer on one of patient's foot&#xD;
&#xD;
          -  the presence of infection or dermatitis on the experimented foot&#xD;
&#xD;
          -  the presence of severe inflammation on the experimented skin (redness score &gt;2 or/and&#xD;
             fissure score &gt;2 measured by SRRC or/and total SRRC score ranged from12-16)&#xD;
&#xD;
          -  estimated glomerular filtration rate value (eGFR) &lt; 45&#xD;
&#xD;
          -  impaired liver function (increased by 2x from upper limit reference for AST/ALT)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suhendro Suhendro, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Indonesia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitas Indonesia</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>Jakarta</state>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 18, 2019</study_first_submitted>
  <study_first_submitted_qc>January 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2019</study_first_posted>
  <last_update_submitted>January 20, 2019</last_update_submitted>
  <last_update_submitted_qc>January 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>Dr. Lili Legiawati, SpKK(K)</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>dry skin</keyword>
  <keyword>dm type 2</keyword>
  <keyword>centella asiatica</keyword>
  <keyword>superoxide dismutase</keyword>
  <keyword>AGEs CML</keyword>
  <keyword>IL-1α</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Petrolatum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

